Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Calcified Tissue International
Published in: Calcified Tissue International 2/2016

Open Access 01-08-2016 | Original Research

Regulation of CYP27B1 mRNA Expression in Primary Human Osteoblasts

Authors: K. van der Meijden, H. W. van Essen, F. W. Bloemers, E. A. J. M. Schulten, P. Lips, N. Bravenboer

Published in: Calcified Tissue International | Issue 2/2016

Login to get access

Abstract

The enzyme 1α-hydroxylase (gene CYP27B1) catalyzes the synthesis of 1,25(OH)2D in both renal and bone cells. While renal 1α-hydroxylase is tightly regulated by hormones and 1,25(OH)2D itself, the regulation of 1α-hydroxylase in bone cells is poorly understood. The aim of this study was to investigate in a primary human osteoblast culture whether parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), calcitonin, calcium, phosphate, or MEPE affect mRNA levels of CYP27B1. Our results show that primary human osteoblasts in the presence of high calcium concentrations increase their CYP27B1 mRNA levels by 1.3-fold. CYP27B1 mRNA levels were not affected by PTH1-34, rhFGF23, calcitonin, phosphate, and rhMEPE. Our results suggest that the regulation of bone 1α-hydroxylase is different from renal 1α-hydroxylase. High calcium concentrations in bone may result in an increased local synthesis of 1,25(OH)2D leading to an enhanced matrix mineralization. In this way, the local synthesis of 1,25(OH)2D may contribute to the stimulatory effect of calcium on matrix mineralization.
Appendix
Available only for authorised users
Literature
1.
Addison WN, Nakano Y, Loisel T, Crine P, McKee MD (2008) MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM. J Bone Miner Res 23:1638–1649CrossRefPubMed
2.
Anderson PH, Atkins GJ (2008) The skeleton as an intracrine organ for vitamin D metabolism. Mol Aspects Med 29:397–406CrossRefPubMed
3.
Anderson PH, Iida S, Tyson JH, Turner AG, Morris HA (2010) Bone CYP27B1 gene expression is increased with high dietary calcium and in mineralising osteoblasts. J Steroid Biochem Mol Biol 121:71–75CrossRefPubMed
4.
Anderson PH, O’Loughlin PD, May BK, Morris HA (2005) Modulation of CYP27B1 and CYP24 mRNA expression in bone is independent of circulating 1,25(OH)2D3 levels. Bone 36:654–662CrossRefPubMed
5.
Atkins GJ, Anderson PH, Findlay DM, Welldon KJ, Vincent C, Zannettino AC, O’Loughlin PD, Morris HA (2007) Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1α,25-dihydroxyvitamin D3. Bone 40:1517–1528CrossRefPubMed
6.
Atkins GJ, Welldon KJ, Holding CA, Haynes DR, Howie DW, Findlay DM (2009) The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles. Biomaterials 30:3672–3681CrossRefPubMed
7.
Bacchetta J, Sea JL, Chun RF, Lisse TS, Wesseling-Perry K, Gales B, Adams JS, Salusky IB, Hewison M (2013) Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res 28:46–55CrossRefPubMedPubMedCentral
8.
Beresford JN, Gallagher JA, Gowen M, McGuire MKB, Poser JW, RGG Russell (1983) Human bone cells in culture: a novel system for the investigation of bone cell metabolism. Clin Sci 64:33–39CrossRef
9.
Bland R, Walker EA, Hughes SV, Stewart PM, Hewison M (1999) Constitutive expression of 25-hydroxyvitamin D3-1α-hydroxylase in a transformed human proximal tubule cell line: evidence for direct regulation of vitamin D metabolism by calcium. Endocrinology 140:2027–2034PubMed
10.
11.
Brunette MG, Chan M, Ferriere C, Roberts KD (1978) Site of 1,25(OH)2 vitamin D3 synthesis in the kidney. Nature 276:287–289CrossRefPubMed
12.
Chattopadhyay N, Yano S, Tfelt-Hansen J, Rooney P, Kanuparthi D, Bandyopadhyay S, Ren X, Terwilliger E, Brown EM (2004) Mitogenic action of calcium-sensing receptor on rat calvarial osteoblasts. Endocrinology 145:3451–3462CrossRefPubMed
13.
Cianferotti L, Gomes AR, Fabbri S, Tanini A, Brandi ML (2015) The calcium-sensing receptor in bone metabolism: from bench to bedside and back. Osteoporos Int 26:2055–2071CrossRefPubMed
14.
Condamine L, Menaa C, Vrtovsnik F, Friedlander G, Garabedian M (1994) Local action of phosphate depletion and insulin-like growth factor 1 on in vitro production of 1,25-dihydroxyvitamin D by cultured mammalian kidney cells. J Clin Invest 94:1673–1679CrossRefPubMedPubMedCentral
15.
Dobbie H, Unwin RJ, Faria NJ, Shirley DG (2008) Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption. Nephrol Dial Transplant 23:730–733CrossRefPubMed
16.
Dvorak MM, Siddiqua A, Ward DT, Carter DH, Dallas SL, Nemeth EF, Riccardi D (2004) Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of calciotropic hormones. Proc Natl Acad Sci USA 101:5140–5145CrossRefPubMedPubMedCentral
17.
Farley JR, Hall SL, Tarbaux NM (1989) Calcitonin (but not calcitonin gene-related peptide) increases mouse bone cell proliferation in a dose-dependent manner, and increases mouse bone formation, alone and in combination with fluoride. Calcif Tissue Int 45:214–221CrossRefPubMed
18.
Farley JR, Wergedal JE, Hall SL, Herring S, Tarbaux NM (1991) Calcitonin has direct effects on 3[H]-thymidine incorporation and alkaline phosphatase activity in human osteoblast-line cells. Calcif Tissue Int 48:297–301CrossRefPubMed
19.
Fukase M, Birge SJ Jr, Rifas L, Avioli LV, Chase LR (1982) Regulation of 25 hydroxyvitamin D3 1-hydroxylase in serum-free monolayer culture of mouse kidney. Endocrinology 110:1073–1075CrossRefPubMed
20.
Gabusi E, Manferdini C, Grassi F, Piacentini A, Cattini L, Filardo G, Lambertini E, Piva R, Zini N, Facchini A, Lisignoli G (2012) Extracellular calcium chronically induced human osteoblasts effects: specific modulation of osteocalcin and collagen type XV. J Cell Physiol 227:3151–3161CrossRefPubMed
21.
Geng S, Zhou S, Glowacki J (2011) Age-related decline in osteoblastogenesis and 1α-hydroxylase/CYP27B1 in human mesenchymal stem cells: stimulation by parathyroid hormone. Aging Cell 10:962–971CrossRefPubMedPubMedCentral
22.
Godwin SL, Soltoff SP (1997) Extracellular calcium and platelet-derived growth factor promote receptor-mediated chemotaxis in osteoblasts through different signaling pathways. J Biol Chem 272:11307–11312CrossRefPubMed
23.
Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA (2003) Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 278:1998–2007CrossRefPubMed
24.
Gray RW (1981) Control of plasma 1,25-(OH)2-vitamin D concentrations by calcium and phosphorus in the rat: effects of hypophysectomy. Calcif Tissue Int 33:485–488CrossRefPubMed
25.
Halloran BP, Spencer EM (1988) Dietary phosphorus and 1,25-dihydroxyvitamin D metabolism: influence of insulin-like growth factor I. Endocrinology 123:1225–1229CrossRefPubMed
26.
Hewison M, Zehnder D, Bland R, Stewart PM (2000) 1α-Hydroxylase and the action of vitamin D. J Mol Endocrinol 25:141–148CrossRefPubMed
27.
Holt E, Wysolmerski JJ (2011) Parathyroid hormone, parathyroid hormone-related protein, and calcitonin. In: Feldman D, Pike JW, Adams JS (eds) Vitamin D, 3rd edn. Academic Press, San Diego, pp 725–745CrossRef
28.
Horiuchi N, Takahashi H, Matsumoto T, Takahashi N, Shimazawa E, Suda T, Ogata E (1979) Salmon calcitonin-induced stimulation of 1α,25-dihydroxycholecalciferol synthesis in rats involving a mechanism independent of adenosine 3′:5′-cyclic monophosphate. Biochem J 184:269–275CrossRefPubMedPubMedCentral
29.
Ito N, Findlay DM, Anderson PH, Bonewald LF, Atkins GJ (2013) Extracellular phosphate modulates the effect of 1α,25-dihydroxy vitamin D3 (1,25D) on osteocyte like cells. J Steroid Biochem Mol Biol 136:183–186CrossRefPubMed
30.
Jung SY, Kwak JO, Kim HW, Kim DS, Ryu SD, Ko CB, Cha SH (2005) Calcium sensing receptor forms complex with and is up-regulated by caveolin-1 in cultured human osteosarcoma (Saos-2) cells. Exp Mol Med 37:91–100CrossRefPubMed
31.
Kawashima H, Torikai S, Kurokawa K (1981) Calcitonin selectively stimulates 25-hydroxyvitamin D3-1α-hydroxylase in proximal straight tubule of rat kidney. Nature 291:327–329CrossRefPubMed
32.
Kulkarni RN, Bakker AD, Everts V, Klein-Nulend J (2010) Inhibition of osteoclastogenesis by mechanically loaded osteocytes: involvement of MEPE. Calcif Tissue Int 87:461–468CrossRefPubMedPubMedCentral
33.
34.
Machado JP, Johnson WE, O’Brien SJ, Vasconcelos V, Antunes A (2011) Adaptive evolution of the matrix extracellular phosphoglycoprotein in mammals. BMC Evol Biol 11:342CrossRefPubMedPubMedCentral
35.
Maeno S, Niki Y, Matsumoto H, Morioka H, Yatabe T, Funayama A, Toyama Y, Taguchi T, Tanaka J (2005) The effect of calcium ion concentration on osteoblast viability, proliferation and differentiation in monolayer and 3D culture. Biomaterials 26:4847–4855CrossRefPubMed
36.
Mailland M, Waelchli R, Ruat M, Boddeke HG, Seuwen K (1997) Stimulation of cell proliferation by calcium and a calcimimetic compound. Endocrinology 138:3601–3605CrossRefPubMed
37.
Marie PJ, Lomri A, Sabbagh A, Basle M (1989) Culture and behavior of osteoblastic cells isolated from normal trabecular bone surfaces. In Vitro Cell Dev Biol 25:373–380CrossRefPubMed
38.
Marie PJ (2010) The calcium-sensing receptor in bone cells: a potential therapeutic target in osteoporosis. Bone 46:571–576CrossRefPubMed
39.
Marks J, Churchill LJ, Debnam ES, Unwin RJ (2008) Matrix extracellular phosphoglycoprotein inhibits phosphate transport. J Am Soc Nephrol 19:2313–2320CrossRefPubMedPubMedCentral
40.
Martin A, David V, Laurence JS, Schwarz PM, Lafer EM, Hedge AM, Rowe PS (2008) Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 149:1757–1772CrossRefPubMed
41.
42.
Morris HA, O’Loughlin PD, Anderson PH (2010) Experimental evidence for the effects of calcium and vitamin D on bone: a review. Nutrients 2:1026–1035CrossRefPubMedPubMedCentral
43.
Murayama A, Takeyama K, Kitanaka S, Kodera Y, Kawaguchi Y, Hosoya T, Kato S (1999) Positive and negative regulations of the renal 25-hydroxyvitamin D3 1α-hydroxylase gene by parathyroid hormone, calcitonin, and 1α,25(OH)2D3 in intact animals. Endocrinology 140:2224–2231PubMed
44.
Nampei A, Hashimoto J, Hayashida K, Tsuboi H, Shi K, Tsuji I, Miyashita H, Yamada T, Matsukawa N, Matsumoto M, Morimoto S, Ogihara T, Ochi T, Yoshikawa H (2004) Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. J Bone Miner Metab 22:176–184CrossRefPubMed
45.
Perwad F, Portale AA (2011) Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23. Mol Cell Endocrinol 347:17–24CrossRefPubMed
46.
Petersen DN, Tkalcevic GT, Mansolf AL, Rivera-Gonzalez R, Brown TA (2000) Identification of osteoblast/osteocyte factor 45 (OF45), a bone-specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes. J Biol Chem 275:36172–36180CrossRefPubMed
47.
48.
Quarles LD, Hartle JE, Middleton JP, Zhang J, Arthur JM, Raymond JR (1994) Aluminum-induced DNA synthesis in osteoblasts: mediation by a G-protein coupled cation sensing mechanism. J Cell Biochem 56:106–117CrossRefPubMed
49.
Quarles LD (1997) Cation sensing receptors in bone: a novel paradigm for regulating bone remodeling? J Bone Miner Res 12:1971–1974CrossRefPubMed
50.
Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL (2000) MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67:54–68CrossRefPubMed
51.
Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR (2004) MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34:303–319CrossRefPubMedPubMedCentral
52.
Shinki T, Ueno Y, DeLuca HF, Suda T (1999) Calcitonin is a major regulator for the expression of renal 25-hydroxyvitamin D3-1α-hydroxylase gene in normocalcemic rats. Proc Natl Acad Sci USA 96:8253–8258CrossRefPubMedPubMedCentral
53.
Silva BC, Bilezikian JP (2015) Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol 22:41–50CrossRefPubMed
54.
Somjen D, Katzburg S, Stern N, Kohen F, Sharon O, Limor R, Jaccard N, Hendel D, Weisman Y (2007) 25 hydroxy-vitamin D3-1α hydroxylase expression and activity in cultured human osteoblasts and their modulation by parathyroid hormone, estrogenic compounds and dihydrotestosterone. J Steroid Biochem Mol Biol 107:238–244CrossRefPubMed
55.
Turner AG, Dwivedi PP, May BK, Morris HA (2007) Regulation of the CYP27B1 5′-flanking region by transforming growth factor-beta in ROS 17/2.8 osteoblast-like cells. J Steroid Biochem Mol Biol 103:322–325CrossRefPubMed
56.
Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770–774CrossRefPubMed
57.
van der Meijden K, Bakker AD, van Essen HW, Heijboer AC, Schulten EAJM, Lips P, Bravenboer N (2015) Mechanical loading and the synthesis of 1,25(OH)2D in primary human osteoblasts. J Steroid Biochem Mol Biol. accepted
58.
van der Meijden K, Lips P, van Driel M, Heijboer AC, Schulten EA, den Heijer M, Bravenboer N (2014) Primary Human Osteoblasts in Response to 25-Hydroxyvitamin D3, 1,25-Dihydroxyvitamin D3 and 24R,25-Dihydroxyvitamin D3. PLoS One 9:e110283CrossRefPubMedPubMedCentral
59.
van Driel M, Koedam M, Buurman CJ, Hewison M, Chiba H, Uitterlinden AG, Pols HA, van Leeuwen JP (2006) Evidence for auto/paracrine actions of vitamin D in bone: 1α-hydroxylase expression and activity in human bone cells. FASEB J. 20:2417–2419CrossRefPubMed
60.
61.
Verstuyf A, Carmeliet G, Bouillon R, Mathieu C (2010) Vitamin D: a pleiotropic hormone. Kidney Int 78:140–145CrossRefPubMed
62.
Villa I, Dal FC, Maestroni A, Rubinacci A, Ravasi F, Guidobono F (2003) Human osteoblast-like cell proliferation induced by calcitonin-related peptides involves PKC activity. Am J Physiol Endocrinol Metab 284:E627–E633CrossRefPubMed
63.
Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K, Aubin JE, Maeda N (2008) Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 23:939–948CrossRefPubMed
64.
Yamauchi M, Yamaguchi T, Kaji H, Sugimoto T, Chihara K (2005) Involvement of calcium-sensing receptor in osteoblastic differentiation of mouse MC3T3-E1 cells. Am J Physiol Endocrinol Metab 288:E608–E616CrossRefPubMed
Metadata
Title
Regulation of CYP27B1 mRNA Expression in Primary Human Osteoblasts
Authors
K. van der Meijden
H. W. van Essen
F. W. Bloemers
E. A. J. M. Schulten
P. Lips
N. Bravenboer
Publication date
01-08-2016
Publisher
Springer US
Published in
Calcified Tissue International / Issue 2/2016
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-016-0131-9

Other articles of this Issue 2/2016

Calcified Tissue International 2/2016 Go to the issue

Original Research

Interleukin-1β Suppresses the Transporter Genes Ank and Ent1 Expression in Stromal Progenitor Cells Retaining Mineralization

Original Research

Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX® in Portugal

Original Research

Icariin Stimulates Differentiation and Suppresses Adipocytic Transdifferentiation of Primary Osteoblasts Through Estrogen Receptor-Mediated Pathway

Original Research

Glutamate Receptor Agonists and Glutamate Transporter Antagonists Regulate Differentiation of Osteoblast Lineage Cells

Original Research

In Vivo Bone Formation Within Engineered Hydroxyapatite Scaffolds in a Sheep Model

Original Research

Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits